Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Retinoblastoma 1 (RB1) mRNA 3'-untranslated region (3'-UTR) is a key regulatory sequence located downstream of the coding region of the RB1 gene, which encodes the pRb tumor suppressor protein. This region serves as a scaffold for the binding of various microRNAs (miRNAs) and RNA-binding proteins (RBPs) that post-transcriptionally regulate RB1 expression by influencing mRNA degradation and translation (Ivanovska et al., 2008, PubMed: 18347084). In several human cancers, oncogenic miRNAs such as miR-106b, miR-17, and miR-20a bind to the RB1 3'-UTR to downregulate pRb levels, thereby promoting aberrant cell cycle progression and tumor growth (Volinia et al., 2006, PubMed: 16477017). Because of its central role in controlling a major tumor suppressor, the RB1 3'-UTR is considered a viable therapeutic target for RNA-targeted therapies, such as antisense oligonucleotides (ASOs) or miRNA inhibitors, designed to prevent miRNA-mediated silencing and restore pRb function. These therapeutic strategies aim to re-engage the G1/S cell cycle checkpoint, particularly in tumors where RB1 is transcriptionally active but post-transcriptionally suppressed. While clinical applications are currently in the research and development phase, the specificity of targeting the 3'-UTR offers a precise mechanism to modulate protein output without altering the genomic sequence.
Modulation of mRNA stability and translation by sterically blocking microRNA binding sites or RNA-binding protein interactions within the 3'-untranslated region.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinoblastoma 1 messenger RNA 3'-untranslated region (RB1 mRNA 3'-UTR) (RB1 mRNA 3'-UTR).